Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records-Reference-Cited by-同舟云学术

Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records

Published:2018-01-12 Issue:4 Volume:20 Page:974-984
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Patorno Elisabetta¹^ORCID,Gopalakrishnan Chandrasekar¹^ORCID,Franklin Jessica M.¹,Brodovicz Kimberly G.²,Masso-Gonzalez Elvira³,Bartels Dorothee B.³⁴,Liu Jun¹,Schneeweiss Sebastian¹

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine; Brigham and Women's Hospital and Harvard Medical School; Boston Massachusetts

2. Global Epidemiology, Boehringer Ingelheim Pharmaceuticals, Inc; Ridgefield Connecticut

3. Corporate Department Global Epidemiology; Boehringer Ingelheim GmbH; Ingelheim Germany

4. Hannover Medical School; Institute for Epidemiology, Social Medicine and Health Systems Research; Hannover Germany

Funder

Boehringer-Ingelheim

Brigham and Women's Hospital

National Institute on Aging

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13184/fullpdf

Reference30 articles.

1. Prevention CfDCa 2014 http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf

2. World Health Organization 2016 http://www.who.int/mediacentre/factsheets/fs312/en/

3. FDA http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf

4. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus;Scirica;N Engl J Med,2013

5. Alogliptin after acute coronary syndrome in patients with type 2 diabetes;White;N Engl J Med,2013

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease;Gut;2024-09-06

2. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study;Movement Disorders;2024-08-27

3. Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims Database;Diabetes Therapy;2024-07-03

4. Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis;Frontiers in Pharmacology;2024-05-23

5. Effectiveness and safety of empagliflozin: final results from the EMPRISE study;Diabetologia;2024-03-21